BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21310550)

  • 1. Association between maximal skin dose and breast brachytherapy outcome: a proposal for more rigorous dosimetric constraints.
    Cuttino LW; Heffernan J; Vera R; Rosu M; Ramakrishnan VR; Arthur DW
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e173-7. PubMed ID: 21310550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients.
    Póti Z; Nemeskéri C; Fekésházy A; Sáfrány G; Bajzik G; Nagy ZP; Bidlek M; Sinkovics I; Udvarhelyi N; Liszkay G; Repa I; Galuska L; Trón L; Mayer A; Esik O
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1022-33. PubMed ID: 15001241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer.
    Perera F; Chisela F; Stitt L; Engel J; Venkatesan V
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1283-90. PubMed ID: 16029783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
    Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cosmetic outcome and incidence of infection with the MammoSite breast brachytherapy applicator.
    Dickler A; Kirk MC; Choo J; Hsi WC; Chu J; Dowlatshahi K; Francescatti D; Shott S; Nguyen C
    Breast J; 2005; 11(5):306-10. PubMed ID: 16174149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late chest wall toxicity after MammoSite breast brachytherapy.
    Brashears JH; Dragun AE; Jenrette JM
    Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity.
    Vargo JA; Verma V; Kim H; Kalash R; Heron DE; Johnson R; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):285-91. PubMed ID: 24268787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chest wall dose in MammoSite breast brachytherapy: radiobiologic estimations of late complication risk based on dose-volume considerations.
    Dragun AE; Aguero EG; Harmon JF; Harper JL; Jenrette JM
    Brachytherapy; 2005; 4(4):259-63. PubMed ID: 16344255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of skin and chest wall dose delivered with multicatheter, Contura multilumen balloon, and MammoSite breast brachytherapy.
    Cuttino LW; Todor D; Rosu M; Arthur DW
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):34-8. PubMed ID: 20350796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the MammoSite radiation therapy system for brachytherapy of breast cancer: results from an international phase II trial.
    Niehoff P; Polgár C; Ostertag H; Major T; Sulyok Z; Kimmig B; Kovács G
    Radiother Oncol; 2006 Jun; 79(3):316-20. PubMed ID: 16780977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated partial-breast irradiation with interstitial implants: the clinical relevance of the calculation of skin doses.
    Ott OJ; Lotter M; Sauer R; Strnad V
    Strahlenther Onkol; 2007 Aug; 183(8):426-31. PubMed ID: 17680222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin and chest wall dose with multi-catheter and MammoSite breast brachytherapy: Implications for late toxicity.
    Cuttino LW; Todor D; Rosu M; Arthur DW
    Brachytherapy; 2009; 8(2):223-226. PubMed ID: 19211310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast cancer.
    Kaufman SA; DiPetrillo TA; Price LL; Midle JB; Wazer DE
    Brachytherapy; 2007; 6(4):286-92. PubMed ID: 17991625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience.
    Chao KK; Vicini FA; Wallace M; Mitchell C; Chen P; Ghilezan M; Gilbert S; Kunzman J; Benitez P; Martinez A
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):32-40. PubMed ID: 17467920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
    Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early European experience with the MammoSite radiation therapy system for partial breast brachytherapy following breast conservation operation in low-risk breast cancer.
    Niehoff P; Ballardini B; Polgár C; Major T; Hammer J; Richetti A; Kovács G
    Breast; 2006 Jun; 15(3):319-25. PubMed ID: 16765284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of the source-skin distance measuring bridge indeed reduces skin teleangiectasia after interstitial boost in breast conserving therapy.
    Georg P; Georg D; Van Limbergen E
    Radiother Oncol; 2005 Mar; 74(3):323-30. PubMed ID: 15763314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute complications of MammoSite brachytherapy: a single institution's initial clinical experience.
    Harper JL; Jenrette JM; Vanek KN; Aguero EG; Gillanders WE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):169-74. PubMed ID: 15629608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute toxicity of high-dose-rate intracavitary brachytherapy with the MammoSite applicator in patients with early-stage breast cancer.
    Richards GM; Berson AM; Rescigno J; Sanghavi S; Siegel B; Axelrod D; Bernik S; Scarpinato V; Mills C
    Ann Surg Oncol; 2004 Aug; 11(8):739-46. PubMed ID: 15249336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation.
    Hepel JT; Tokita M; MacAusland SG; Evans SB; Hiatt JR; Price LL; DiPetrillo T; Wazer DE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1290-6. PubMed ID: 19395195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.